These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 11868781)

  • 1. Current strategies for chemoprevention of hepatocellular carcinoma.
    Okita K; Sakaida I; Hino K
    Oncology; 2002; 62 Suppl 1():24-8. PubMed ID: 11868781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma].
    Kubo S; Nishiguchi S; Hirohashi K; Tanaka H; Shuto T; Takemura S; Shiomi S; Kinoshita H
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):1975-9. PubMed ID: 11791377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon and hepatocellular carcinoma.
    Koretz RL
    Lancet; 1996 Jan; 347(8995):194-5. PubMed ID: 8544565
    [No Abstract]   [Full Text] [Related]  

  • 4. Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.
    Della Corte C; Aghemo A; Colombo M
    World J Gastroenterol; 2013 Mar; 19(9):1359-71. PubMed ID: 23538741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of antiviral treatment for HCC prevention.
    Colombo M; Iavarone M
    Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):771-81. PubMed ID: 25260307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)].
    Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Hayashi N; Kasahara A
    Oncology; 2002; 62 Suppl 1():87-93. PubMed ID: 11868793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection.
    Baffis V; Shrier I; Sherker AH; Szilagyi A
    Ann Intern Med; 1999 Nov; 131(9):696-701. PubMed ID: 10577333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causes of and prevention strategies for hepatocellular carcinoma.
    Cabibbo G; Maida M; Genco C; Antonucci M; Cammà C
    Semin Oncol; 2012 Aug; 39(4):374-83. PubMed ID: 22846856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma].
    Lengyel G; Fehér J
    Orv Hetil; 2010 Jul; 151(29):1177-81. PubMed ID: 20591786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatocellular carcinoma.
    Colombo M; Donato MF
    Semin Liver Dis; 2005; 25(2):155-61. PubMed ID: 15918144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of HCV cirrhosis in patients awaiting liver transplantation and prevention of hepatocellular carcinoma].
    Testino G
    Recenti Prog Med; 2007 Apr; 98(4):252-8. PubMed ID: 17547364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?].
    Harada H; Iga D; Arisaka Y; Mitsuhashi Y; Kamitsukasa H; Yagura M; Endou H; Kawashima H
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):754-8. PubMed ID: 7563870
    [No Abstract]   [Full Text] [Related]  

  • 15. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.
    Hoshida Y; Fuchs BC; Bardeesy N; Baumert TF; Chung RT
    J Hepatol; 2014 Nov; 61(1 Suppl):S79-90. PubMed ID: 25443348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.
    Lodato F; Mazzella G; Festi D; Azzaroli F; Colecchia A; Roda E
    World J Gastroenterol; 2006 Dec; 12(45):7239-49. PubMed ID: 17143937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can therapy of hepatitis C affect the development of hepatocellular carcinoma?
    Kulik LM
    J Natl Compr Canc Netw; 2006 Sep; 4(8):751-7. PubMed ID: 16948953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma.
    Kumada H
    Oncology; 2002; 62 Suppl 1():94-100. PubMed ID: 11868794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives.
    Okuno M; Kojima S; Moriwaki H
    J Gastroenterol Hepatol; 2001 Dec; 16(12):1329-35. PubMed ID: 11851828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.